News release: Call for human rights-based guidance on PrEP and ART as prevention
Monday, 18 July 2011
Amsterdam, 18 July 2011 - Preliminary results from two large studies have now shown that a daily antiretroviral tablet taken by people who do not have HIV reduces their risk of contracting HIV by up to 73%. The Partners PrEP trial involved 4758 HIV-discordant couples in Kenya and Uganda. The TDF2 trial involved 1219 men and women in Botswana.
The studies looked at both tenofovir or tenofovir plus emtricitabine (Truvada) and found that each, when taken in advance by the HIV-negative partner as a pre-exposure prophylaxis (PrEP), can prevent heterosexual transmission of HIV from men to women and from women to men.





